Steve H. Thorne

OSE Immunotherapeutics (France) — France

Biochemistry, Genetics and Molecular Biology · Life Sciences

31h-index4.3kcitations96works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(66), Viral Infectious Diseases and Gene Expression in Insects(40), Cancer Research and Treatments(40), CAR-T cell therapy research(33), Immunotherapy and Immune Responses(12)

Publications95 total

Abstract 484: Mechanisms of synergy between TGF-beta inhibitor and IL12 expression from the systemically deliverable clinical oncolytic immunotherapy VET3-TGI
Cancer Research·2025
1394 Novel oncolytic viral immunotherapy VET3-TGI displays enhanced systemic delivery and inhibits TGFb-signaling while augmenting type-1 immune response in the tumor
Regular and Young Investigator Award Abstracts·2023Open Access
Abstract 6789: The oncolytic virus VET3-TGI both blocks TGF-beta signaling and activates type 2 IFN responses, resulting in potent therapeutic responses in multiple mouse models
Cancer Research·2023
Data from CNOB/ChrR6, a new prodrug enzyme cancer chemotherapy
2023Open Access
Supplemental Figures S1-5 from Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
2023Open Access
Supplementary Fig. from CNOB/ChrR6, a new prodrug enzyme cancer chemotherapy
2023Open Access
Data from CNOB/ChrR6, a new prodrug enzyme cancer chemotherapy
2023Open Access
Supplementary Fig. from CNOB/ChrR6, a new prodrug enzyme cancer chemotherapy
2023Open Access
Data from Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
2023Open Access
Data from Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
2023Open Access
Supplemental Figures S1-5 from Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
2023Open Access
Supplementary Methods from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
Supplementary Figure 3 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
Supplementary Figure 2 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
Data from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
Supplementary Figure 2 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
Supplementary Table 1 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
Supplementary Figure 4 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
Supplementary Figures 1-3 from Definition of an Enhanced Immune Cell Therapy in Mice That Can Target Stem-Like Lymphoma Cells
2023Open Access
Supplementary Video 2 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Padma Sampath(11), David H. Kirn(10), Christopher H. Contag(8), John C. Bell(6), Weizhou Hou(6), David L. Bartlett(5), Juan J. Rojas(5), Tae-Ho Hwang(3), Robert S. Negrin(3), Hannah Chen(3), Fabrice Le Bœuf(3), William O’Gorman(3), Mark E. O’Malley(3), Rachel Sikorski(3), Caroline J. Breitbach(2), Rozanne Arulanandam(2), Carolina S. Ilkow(2), Christina Addison(2), Tony Reid(2), Yaohe Wang(2)